• Clinical antiplatelet effectiveness is reduced for poor metabolizers of clopidogrel. 
• Genetic tests are available to identify poor metabolizers.
• Emerging role of genetic testing in clopidogrel treatment decisions

Read full clinical alert in Circulation

Editorial: Responding to the Clopidogrel Warning by the US Food and Drug Administration: Real Life Is Complicated
by Dan M. Roden, M.D., and Alan R. Shuldiner, M.D.

Supporting Materials

• Summary Slide
• 21 CFR 201.57 - Specific requirements on content and format of labeling for human prescription drugs.
• DA Drug Safety Communication: Reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug

Other AHA Statements on Anticoagulation

• Prevention of Premature Discontinuation of Dual Antiplatelet Therapy in Patients With Coronary Artery Stents
• Anticoagulants and Antiplatelet Agents in Acute Ischemic Stroke